Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages 1254-1262

  Rossi, Antonio ^a   Chiodini, Paolo ^b   Sun, Jong Mu ^c   O'Brien, Mary E R ^d   von Plessen, Christian ^e,f   Barata, Fernando ^g   Park, Keunchil ^c   Popat, Sanjay ^d   Bergman, Bengt ^h   Parente, Barbara ⁱ   Gallo, Ciro ^b   Gridelli, Cesare ^a   Perrone, Francesco ^j   Di Maio, Massimo ^j  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e HILLERØD HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^j NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGE DISTRIBUTION; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXPLORATORY RESEARCH; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84908137867     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70402-4     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guidelines update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
3. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii56-vii64.
4. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines in advanced disease. Ann Oncol 2014, 25:1475-1484.
5. Non-small cell lung cancer. Version 3 NCCN Clinical Practice Guidelines in Oncology, (accessed May 1, 2014). http://www.nccn.com.
6. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
7. Cappuzzo F, Ciuleanu T, Stelmakh, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
8. Johnson BE, Kabbinavar F, Fehrenbacher L, et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with and without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013, 31:3926-3934.
9. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013, 31:2895-2902.
10. Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-small cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014, 25:1044-1052.
11. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced nonsmall-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001, 19:1336-1343.
12. von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer. Br J Cancer 2006, 95:966-973.
13. Park JO, Kim S-W, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol 2007, 25:5233-5239.
14. Lima JP, dos Santos LV, Sasse EC, Sasse AD Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 2009, 45:601-607.
15. Soon YY, Stockler MR, Askie LM, Boyer MJ Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009, 27:3277-3283.
16. Barata FJ, Parente B, Teixeira E, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine. J Thorac Oncol 2007, 2(suppl 4):S666. (abstr P2-235).
17. Schemper M, Smith TL A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
18. Smith CT, Williamson PR, Marson AG Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 2005, 24:1307-1319.
19. Reis IM, Hirji KF, Afifi AA Exact and asymptotic tests for homogeneity in several 2 × 2 tables. Stat Med 1999, 18:893-906.
20. Tourani JM, Penaud D, Caubarrere I, et al. Cisplatin and vindesine for disseminated non-small cell lung cancer. Results of a prospective trial with 81 patients. Bull Cancer 1990, 77:1107-1113.
21. Grossi F, Belvedere O, Defferrari C, et al. Optimal duration of chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC) in the 1st and 2nd line settings. J Thorac Oncol 2009, 4(suppl 1):S682-S683. (abstr P1.184).
22. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M The prognostic and predictive role of histology in advanced non-small cell lung cancer. A literature review. J Thorac Oncol 2008, 3:1468-1481.